Home Venture Capital & Startup Funding Hyun-Jin Bae Co-Founder and CEO of PROMEDIUS tells CB Insights how they view the market customer needs and their company

Hyun-Jin Bae Co-Founder and CEO of PROMEDIUS tells CB Insights how they view the market customer needs and their company

by Laily UPN

The medical imaging landscape is undergoing a profound transformation driven by artificial intelligence, and at the center of this shift is PROMEDIUS, a South Korean health-tech firm specializing in AI-powered diagnostic solutions. In a recent dialogue with CB Insights, Co-Founder and CEO Hyun-Jin Bae articulated a bold, growth-oriented strategy that underscores the company’s commitment to capturing a significant share of the global chest X-ray screening market. Central to this strategy is a pragmatic approach to commercial partnerships, with Bae emphasizing that the company’s commitment to its mission supersedes any single corporate alliance, including its well-documented collaboration with Daewoong Pharmaceutical. "If Daewoong is not performing, we will do our best; we will hire more salespersons and go with or without Daewoong Pharmaceutical," Bae asserted, highlighting the company’s internal readiness to pivot toward direct sales if external channels fail to meet the rigorous demands of the evolving diagnostic market.

The Macroeconomic Context of AI Diagnostics

The global market for medical imaging AI is projected to reach several billion dollars within the next decade, with chest X-ray screening serving as the primary gateway for early disease detection. For PROMEDIUS, the target demographic is patients over the age of 50, a population segment where the prevalence of chronic respiratory and cardiac conditions is statistically highest. The firm estimates an addressable market starting at approximately 3 billion chest X-ray studies annually, with each study representing roughly $3 of potential value in AI-augmented diagnostic efficiency.

This market valuation is not merely speculative; it is rooted in the increasing burden on radiologists worldwide. As global populations age, the volume of radiological studies has outpaced the growth of the physician workforce. By deploying AI algorithms to triage and analyze X-rays, PROMEDIUS aims to reduce the "time to diagnosis," thereby lowering hospital operational costs and improving patient outcomes through faster intervention.

Chronology and Strategic Milestones

The trajectory of PROMEDIUS has been characterized by aggressive product development and strategic scaling. Founded with the intent to bridge the gap between complex deep learning architectures and clinical utility, the company spent its formative years refining its proprietary algorithms for high-accuracy chest imaging.

  • Early Phase: Initial R&D focus on deep learning models designed to detect pulmonary nodules, pleural effusions, and cardiomegaly.
  • Expansion Phase: Securing regulatory clearances for core software products, allowing for integration into hospital Picture Archiving and Communication Systems (PACS).
  • Partnership Era: The formation of the strategic alliance with Daewoong Pharmaceutical marked a critical milestone in the company’s commercial lifecycle. The partnership was designed to leverage Daewoong’s extensive sales force and deep-rooted relationships with hospitals across South Korea and Southeast Asia to accelerate market penetration.
  • The Pivot Point: Recent internal reviews have led leadership to reassess the efficiency of outsourced distribution. Bae’s recent commentary reflects a shift toward "operational sovereignty," where the company is prepared to internalize sales and marketing functions to ensure that market penetration remains aligned with the firm’s aggressive growth targets.

The Economics of AI-Driven Radiology

The estimation of $3 per study is a metric that reflects both the competitive pricing landscape and the scalability of Software-as-a-Medical-Device (SaMD) products. In the traditional medical imaging paradigm, the cost is tied to human labor, equipment maintenance, and time-intensive manual interpretation. PROMEDIUS’s model proposes that the marginal cost of processing an additional scan via their AI engine is significantly lower, offering a high-margin value proposition to hospital administrators.

However, this pricing model is subject to sensitivity. Market analysts point to several variables that could force a revision of this estimate:

CEO Interview: PROMEDIUS
  1. Reimbursement Policies: The extent to which national health insurance systems or private insurers provide coverage for AI-assisted diagnostic reports will dictate the ceiling on pricing.
  2. Competitive Saturation: As more entrants populate the AI radiology space, pricing pressure may force a reduction in per-study value, forcing companies to rely on volume-based scaling.
  3. Regulatory Hurdles: Stricter validation requirements by agencies like the FDA or the MFDS (Ministry of Food and Drug Safety in South Korea) may increase the cost of maintaining software compliance, potentially eating into the $3 margin.

The Relationship with Daewoong Pharmaceutical

The public statement regarding Daewoong Pharmaceutical is indicative of a broader trend in the health-tech sector where startups are increasingly wary of "distribution friction." While large pharmaceutical firms offer established pipelines, they are often burdened by legacy operational structures. For a nimble AI firm like PROMEDIUS, the speed of adoption is paramount.

If the internal assessment determines that the partnership is failing to capture the intended market velocity, the decision to hire an independent sales force is a logical, albeit costly, hedge. This move suggests that PROMEDIUS is shifting from a "product-led" startup phase to an "execution-led" growth phase, where the control of the customer relationship becomes as important as the quality of the algorithm itself.

Broader Industry Implications

The aggressive stance taken by PROMEDIUS serves as a case study for other AI startups navigating the complex landscape of medical distribution. The industry has historically seen many AI firms succumb to the "pilot purgatory"—a state where software is successfully trialed in hospitals but fails to achieve widespread, recurring commercial use. By signaling a willingness to go direct, PROMEDIUS is attempting to avoid this trap.

Furthermore, the focus on the over-50 demographic is a strategic masterclass in identifying where the greatest clinical and economic value lies. In this demographic, the incidence of comorbidities is high, and the necessity for serial imaging—repeated X-rays over time—creates a recurring revenue model. This creates a "sticky" user base where hospitals are less likely to churn away from the software once the clinical workflow has been integrated.

Future Outlook and Strategic Analysis

Looking ahead, the success of PROMEDIUS will likely hinge on three key factors: the accuracy of its longitudinal data, its ability to integrate with diverse PACS environments, and its agility in navigating local regulatory frameworks. The potential to scale beyond South Korea into larger markets like North America and Europe will require not only superior technology but also a sophisticated understanding of localized billing and clinical integration.

The skepticism regarding the $3-per-study valuation is a healthy part of the company’s internal discourse. Bae’s team is actively analyzing which of these inputs might require revision, acknowledging that the volatility of the global healthcare economy requires constant recalibration. If inflation continues to impact hospital capital expenditure, the willingness of healthcare systems to pay for non-mandatory diagnostic aids may fluctuate, necessitating a more flexible, perhaps subscription-based or outcome-based, pricing model.

In conclusion, the statements from Hyun-Jin Bae underscore a company that is acutely aware of the competitive pressures of the medical AI sector. By prioritizing market penetration over the convenience of existing partnerships, PROMEDIUS is positioning itself to be a primary architect of the future of digital diagnostics. Whether the future involves continued collaboration with incumbents or a radical shift toward direct-to-hospital sales, the company remains focused on the core mission of providing scalable, accurate, and accessible diagnostic intelligence to a global market that is increasingly reliant on AI to bridge the widening gap in clinical care capacity. The next 18 to 24 months will be critical in determining whether this bold internal strategy translates into sustained market dominance.

You may also like